Versican Plus DHPPi

Valsts: Eiropas Savienība

Valoda: angļu

Klimata pārmaiņas: EMA (European Medicines Agency)

Aktīvā sastāvdaļa:

canine distemper virus, strain CDV Bio 11/A, canine adenovirus type 2, strain CAV-2 Bio 13, canine parvovirus type 2b, strain CPV-2b Bio 12/B and canine parainfluenza type 2 virus, strain CPiV-2 Bio 15 (all live attenuated)

Pieejams no:

Zoetis Belgium SA

ATĶ kods:

QI07AD04

SNN (starptautisko nepatentēto nosaukumu):

canine distemper virus, canine adenovirus, canine parvovirus, canine parainfluenza virus

Ārstniecības grupa:

Dogs

Ārstniecības joma:

Immunologicals for canidae, Live viral vaccines

Ārstēšanas norādes:

Active immunisation of dogs from six weeks of age.to prevent mortality and clinical signs caused by canine distemper virus,to prevent mortality and clinical signs caused by canine adenovirus type 1,to prevent clinical signs and reduce viral excretion caused by canine adenovirus type 2,to prevent clinical signs, leukopenia and viral excretion caused by canine parvovirus,to prevent clinical signs and reduce viral excretion caused by canine parainfluenza virus.

Produktu pārskats:

Revision: 7

Autorizācija statuss:

Authorised

Autorizācija datums:

2014-07-03

Lietošanas instrukcija

17
B. PACKAGE LEAFLET
18
PACKAGE LEAFLET:
VERSICAN PLUS DHPPI LYOPHILISATE AND SOLVENT FOR SUSPENSION FOR
INJECTION FOR DOGS
1.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE
FOR BATCH RELEASE, IF DIFFERENT
Marketing authorisation holder:
Zoetis Belgium SA
Rue Laid Burniat 1
1348 Louvain-la-Neuve
BELGIUM
Manufacturer responsible for batch release:
Bioveta, a.s.,
Komenského 212,
683 23 Ivanovice na Hané,
CZECH REPUBLIC
2.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Versican Plus DHPPi lyophilisate and solvent for suspension for
injection for dogs
3.
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)
Each dose of 1 ml contains:
ACTIVE SUBSTANCES:
LYOPHILISATE (LIVE ATTENUATED):
MINIMUM
MAXIMUM_ _
Canine distemper virus, strain CDV Bio 11/A
10
3.1
TCID
50
*
10
5.1
TCID
50
Canine adenovirus Type 2, strain CAV-2 Bio 13
10
3.6
TCID
50
*
10
5.3
TCID
50
Canine parvovirus Type 2b, strain CPV-2b Bio 12/B
10
4.3
TCID
50
*
10
6.6
TCID
50
Canine parainfluenza Type 2 virus, strain CPiV-2 Bio 15
10
3.1
TCID
50
*
10
5.1
TCID
50
SOLVENT:
Water for injections (
_Aqua ad iniectabilia_
)
1 ml
*
Tissue culture infectious dose 50%.
Lyophilisate: spongy matter of white colour.
Solvent: clear colourless liquid.
4.
INDICATION(S)
Active immunisation of dogs from 6 weeks of age:
−
to prevent mortality and clinical signs caused by canine distemper
virus,
−
to prevent mortality and clinical signs caused by canine adenovirus
type 1,
19
−
to prevent clinical signs and reduce viral excretion caused by canine
adenovirus type 2,
−
to prevent clinical signs, leucopoenia and viral excretion caused by
canine parvovirus, and
−
to prevent clinical signs (nasal and ocular discharge) and reduce
viral excretion caused by
canine parainfluenza virus.
Onset of immunity:
−
3 weeks after the first vaccination for CDV, CAV, CPV, and
−
3 weeks after completion of the primary course for CPiV.
Duration of immunity:
At least three years following the primary vaccination course

Produkta apraksts

1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Versican Plus DHPPi lyophilisate and solvent for suspension for
injection for dogs
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each dose of 1 ml contains:
ACTIVE SUBSTANCES:
LYOPHILISATE (LIVE ATTENUATED):
MINIMUM
MAXIMUM_ _
Canine distemper virus, strain CDV Bio 11/A
10
3.1
TCID
50
*
10
5.1
TCID
50
Canine adenovirus Type 2, strain CAV-2 Bio 13
10
3.6
TCID
50
*
10
5.3
TCID
50
Canine parvovirus Type 2b, strain CPV-2b Bio 12/B
10
4.3
TCID
50
*
10
6.6
TCID
50
Canine parainfluenza Type 2 virus, strain CPiV-2 Bio 15
10
3.1
TCID
50
*
10
5.1
TCID
50
SOLVENT:
Water for injections (
_Aqua ad iniectabilia_
)
1 ml
*
Tissue culture infectious dose 50%.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Lyophilisate and solvent for suspension for injection.
The visual appearance is as follows:
Lyophilisate: spongy matter of white colour.
Solvent: clear colourless liquid.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dogs
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Active immunisation of dogs from 6 weeks of age:
−
to prevent mortality and clinical signs caused by canine distemper
virus,
−
to prevent mortality and clinical signs caused by canine adenovirus
type 1,
−
to prevent clinical signs and reduce viral excretion caused by canine
adenovirus type 2,
−
to prevent clinical signs, leucopoenia and viral excretion caused by
canine parvovirus, and
−
to prevent clinical signs (nasal and ocular discharge) and reduce
viral excretion caused by
canine parainfluenza virus.
Onset of immunity:
−
3 weeks after the first vaccination for CDV, CAV, CPV, and
−
3 weeks after completion of the primary course for CPiV.
3
Duration of immunity:
At least three years following the primary vaccination course for
canine distemper virus, canine
adenovirus type 1, canine adenovirus type 2 and canine parvovirus. The
duration of immunity against
CAV-2 was not established by challenge. It was shown that 3 years
after the v